Physician profile
Christopher S Johnson
NPI 1508824871
$3,391.14
in general payments reported to CMS, 2019-2025
32 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.57 · 2020: $168 · 2021: $262 · 2022: $608 · 2023: $819 · 2024: $763 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,321.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $787.60 | 2020-2025 | |
| Lilly USA, LLC | $396.34 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $326.61 | 2021-2025 | |
| Novo Nordisk INC | $288.43 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $288.18 | 2020-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $245.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $111.10 | 2020-2025 | Veozah |
| Dynavax Technologies Corporation | $105.94 | 2024-2025 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.88 | 2023-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $70.16 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $63.46 | 2022 | |
| Supernus Pharmaceuticals, INC. | $60.94 | 2023-2024 | Qelbree |
| Allergan, INC. | $56.19 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.31 | 2021-2023 | |
| Exact Sciences Corporation | $46.89 | 2023-2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $40.24 | 2024 | |
| Phathom Pharmaceuticals, INC. | $37.05 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $35.24 | 2019-2020 | |
| Sanofi Pasteur INC. | $34.77 | 2025 | |
| Organon LLC | $32.44 | 2024-2025 | Nexplanon |
| Exeltis, USA INC. | $30.98 | 2022-2023 | Slynd |
| Biohaven Pharmaceuticals, INC. | $26.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.76 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $23.65 | 2020-2021 | |
| Dexcom, INC. | $17.78 | 2025 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $17.50 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $17.37 | 2021 | |
| Genentech USA, INC. | $17.24 | 2021 | |
| Biogen, INC. | $16.34 | 2025 | Skyclarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.51 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.